Marco is an AI agent available on WhatsApp and Web that allows oncologists to access the latest scientific evidence from thousands of papers, clinical guidelines, and international trials in seconds. It reduces bibliographic search time and improves the quality of clinical decision-making in oncology.
Some answers to questions we often receive
Marco accesses thousands of validated sources including PubMed, NCCN, ESMO, ASCO, FDA, ClinicalTrials.gov, and top-tier oncology publications, updated in real time.
No. Marco is a decision-support tool that synthesizes scientific evidence. The clinical decision always rests with the treating physician, who can evaluate the specific context of each patient.
Yes. Marco can synthesize the most relevant evidence for a specific case —updated therapeutic options, comparative efficacy data, active clinical trials— facilitating the preparation of high-level tumor board presentations.
Marco is available in English, Spanish, and Portuguese, making it accessible for oncologists across Latin America, the US, Europe, and beyond.
Marco includes direct references to the papers, guidelines, and sources used in each response, allowing the physician to verify the evidence and access the original studies with a single click.
Yes. Marco is updated with the latest evidence on immunotherapy, checkpoint inhibitors, CAR-T therapies, ADCs, and other innovative oncology treatments, including data from ongoing clinical trials.
Oncologists don't have time to review dozens of papers every week but need to make clinical decisions based on the latest available evidence.
